ClinicalTrials.gg

Program

Cabergoline

Also written as “Cabergoline tablets test formulation”, “Cabergoline tablets reference formulation” and “Cabergoline tablets”.

Its studies are mostly in Hyperprolactinemia · Restless Legs Syndrome · Adrenocortical Hyperfunction · Acromegaly · Fasting, led by 4 companies.

Furthest: phase 4, since Aug 3, 20258 company-led studies, 2 open or runningNext primary completion: Nov 21, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical22 open or runningphase 3since Aug 3, 2025May 29, 2025Nov 21, 2026phase 3 · NCT07124221
Novartis20 open or runningphase 4since Sep 13, 2006Sep 13, 2006none ahead
Par Health20 open or runningphase 1since Apr 1, 2008Apr 1, 2008none ahead
Pfizer20 open or runningphase 3since Feb 19, 2008Feb 19, 2008none ahead

Also a collaborator on its studies: anapharm.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2006First study: phase 4 study in AcromegalyNew to NovartisNovartis · NCT00376064 · 20 enrolled · Germany
  2. Feb 19, 2008Pfizer's first studies: 2 phase 3 studies in Restless Legs SyndromeNew to PfizerPfizer · NCT00627003, NCT00625547
  3. Apr 1, 2008Par Health's first studies: 2 phase 1 studiesNew to Par HealthPar Health · NCT00653055, NCT00652873
  4. Jun 10, 2013Phase 2 study in Adrenocortical HyperfunctionNovartis · NCT01915303 · 68 enrolled · United States, Argentina, Belgium and more
  5. May 29, 2025Changchun GeneScience Pharmaceutical's first study: phase 1 study in HyperprolactinemiaNew to Changchun GeneScience PharmaceuticalChangchun GeneScience Pharmaceutical · NCT07008417 · 72 enrolled · China
  6. Aug 3, 2025Phase 3 study in HyperprolactinemiaChangchun GeneScience Pharmaceutical · NCT07124221 · 382 planned · China

Ahead

  1. Nov 21, 2026Primary completion: phase 3 study in HyperprolactinemiaChangchun GeneScience Pharmaceutical · NCT07124221

TargetBeta

DRD2 →read by rule
“Dopamine D2 receptor agonist”ChEMBL 37, by rule

Other programs on DRD2

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
rotigotineruleUCBphase 464
lurasidoneruleSumitomo Pharmaphase 452
PramipexoleruleBoehringer Ingelheimphase 444
iloperidoneruleVanda Pharmaceuticalsphase 415
cariprazineruleAbbViephase 341
lumateperoneruleJohnson & Johnsonphase 325
pridopidineruleprileniaphase 310

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07124221Hyperprolactinemia · China3RecruitingChangchun GeneScience PharmaceuticalNov 21, 2026382
NCT07008417Hyperprolactinemia · China1Active, not recruitingChangchun GeneScience PharmaceuticalFeb 3, 202672
NCT01915303Adrenocortical Hyperfunction · United States, Argentina, Belgium and more2TerminatedNovartisSep 5, 201668
NCT00653055Fasting · Canada1CompletedPar HealthDec 200140
NCT00652873Lecithin Cholesterol Acyltransferase Deficiency · Canada1CompletedPar HealthDec 200124
NCT00627003Restless Legs Syndrome3CompletedPfizer43
NCT00625547Restless Legs Syndrome · Austria, Germany, Sweden and more3CompletedPfizer361
NCT00376064Acromegaly · Germany4CompletedNovartisJan 201020

How it is read

Names in the registry

  • “Cabergoline”, 3 entries
  • “Cabergoline tablets test formulation”, 1 entry
  • “Cabergoline tablets reference formulation”, 1 entry
  • “Cabergoline tablets”, 1 entry
  • “Pasireotide with or without cabergoline”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.